Align Technology Names Kevin Conroy Board Chairman as Longtime Chair Ray Larkin Begins Leadership Transition Align Technology, Inc., the global medical device company best known for its Invisalign clear aligner system and broader portfolio of digital dentistry technologies, has announced…
Imperative Care Reports New SYMPHONY-PE Analysis Highlighting Potential Benefits of Early Thrombectomy as Symphony Use Surpasses 500 U.S. Patients Imperative Care, a medical technology company focused on improving treatment options for patients with thromboembolic disease, has announced new clinical findings…
Gossamer Bio Announces Final Results of Convertible Notes Exchange Offer, Strengthening Financial Position Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on advancing therapies for pulmonary hypertension, has announced the final results of its previously disclosed exchange offer involving its…
Hologic Secures Major Patent Victory Against Siemens in European Mammography Technology Dispute Hologic has announced a significant legal victory in Europe after the Unified Patent Court (UPC) in Germany ruled that Siemens Healthineers infringed a key Hologic patent related to…
Emmecell Secures Strategic Financing to Advance Magnetic Cell Delivery Technology for Ophthalmic Diseases Emmecell, a clinical-stage biotechnology company focused on developing innovative magnetic cell delivery technologies for the treatment of ophthalmic disorders, has announced the successful completion of a strategic…
Sumitomo Pharma America Highlights New Clinical and Translational Research for Nuvisertib and Enzomenib at EHA 2026 Sumitomo Pharma America, Inc. (SMPA) has unveiled new clinical and translational research findings at the 2026 Congress of the European Hematology Association (EHA), showcasing…
Atara Biotherapeutics Announces Board Transition, Welcomes Veteran Investor Brian Cherry as Director Atara Biotherapeutics, Inc., a clinical-stage biotechnology company focused on advancing T-cell immunotherapies for cancer and autoimmune diseases, has announced a significant change to its Board of Directors. The…
Xeris Receives USPTO Notice of Allowance for New Patent Covering KEVEYIS®, Extending Potential Protection Through 2039 Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc., has announced a significant intellectual property milestone for KEVEYIS® (dichlorphenamide), its FDA-approved treatment…
Zetagen Therapeutics Reports Promising Phase 2a Results for Investigational ZetaMet™ in Metastatic Breast Cancer Patients With Lytic Bone Lesions Zetagen Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for primary and metastatic breast cancer, has released updated preliminary…
GENESIS Pharma and Alnylam Expand Strategic Partnership to Bring RNAi Therapies to Nordic Markets GENESIS Pharma has announced a significant expansion of its long-standing collaboration with Alnylam Pharmaceuticals, further strengthening the relationship between the two companies and broadening patient access…
Poxel Appoints Yves Decadt as Chief Executive Officer to Lead Next Phase of Growth and Strategic Development French biopharmaceutical company Poxel has announced the appointment of Yves Decadt as its new Chief Executive Officer, effective June 10, 2026. The leadership…
OpenEvidence and the American Academy of Ophthalmology Partner to Bridge the Gap Between Evidence and Clinical Eye Care American Academy of Ophthalmology, the world’s largest association of eye physicians and surgeons, has announced a strategic partnership with OpenEvidence to integrate…